Goldman Sachs U.S. Equity Dividend and Premium Fund Investor Class (GVIRX) kopieguldījumu fonda cena un jaunumi — Google finanses

Finanses

SākumlapaGVIRX • Ieguldījumu fonds

Goldman Sachs U.S. Equity Dividend and Premium Fund Investor Class

18,33 $

27. febr. · USD · MUTF · Atruna

Goldman Sachs U.S. Equity Dividend and Premium Fund Class R6

18,31 $

GIDWX0,44%

Goldman Sachs U.S. Equity Dividend and Premium Fund Institutional Class

18,32 $

GSPKX0,43%

Goldman Sachs U.S. Equity Dividend and Premium Fund Class C

18,28 $

GSPQX0,49%

Goldman Sachs U.S. Equity Dividend and Premium Fund Class P

18,31 $

GSFPX0,49%

Goldman Sachs U.S. Equity Dividend and Premium Fund Class A

18,39 $

GSPAX0,43%

Invesco Income Advantage U.S. Fund Class Y

12,21 $

SCAYX0,25%

Horizon Equity Premium Income Fund Investor Class

81,21 $

HNDDX0,14%

Lincoln U.S. Equity Income Maximizer Fund Class A

11,90 $

LFTOX0,55%

Invesco Income Advantage U.S. Fund Investor Class

12,20 $

SCNUX0,25%

Ieguldījumu fonds

Slēgšanas kurss

18,42 $

Peļņa no gada sākuma

1,54%

Izdevumu koeficients

0,76%

Kategorija

Equity Miscellaneous

Morningstar vērtējums

Neto aktīvi

499,97 milj. USD

Peļņa

1,01%

Komisija

-

Ieviešanas datums

2010. gada 31. aug.

Tirgus ziņas

pirms 22 stundām

FreeCast Inc. (Nasdaq: CAST) Announces Rescheduling of Direct Listing to March 10, 2026

Intellia Therapeutics

pirms 2 dienām

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Quiver Quantitative

pirms 21 stundas

XTL Biopharmaceuticals Limited Faces Nasdaq Delisting Following Insolvency of Subsidiary The Social Proxy

pirms 21 stundas

Nasdaq moves to delist XTL Biopharmaceuticals (XTLB) after shell status finding

Investor's Business Daily

pirms 1 stundas

Trump, Israel Launch 'Massive' Attacks On Iran; How Will Dow Jones Futures React?

pirms 6 stundām

QQQI: Buying The Nasdaq-100, But More Cautiously

Meklēšana

Notīrīt meklēšanu

Aizvērt meklēšanas lodziņu

Google lietotnes

Galvenā izvēlne